2006
DOI: 10.1155/2006/434761
|View full text |Cite
|
Sign up to set email alerts
|

Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment

Abstract: In the multidisciplinary management of gastrointestinal stromal tumours (GISTs), there is a need to coordinate the efforts of pathology, radiology, surgery and oncology. Surgery is the mainstay for resectable nonmetastatic GISTs, but virtually all GISTs are associated with a risk of metastasis. Imatinib 400 mg/day with or without surgery is the recommended first-line treatment for recurrent or metastatic GIST; a higher dose may be considered in patients who progress, develop secondary resistance or present wit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
98
0
5

Year Published

2008
2008
2017
2017

Publication Types

Select...
6
2
1

Relationship

1
8

Authors

Journals

citations
Cited by 123 publications
(105 citation statements)
references
References 47 publications
2
98
0
5
Order By: Relevance
“…Chemotherapy (Imatinib) is the treatment of choice for patients with recurring or metastatic GIST. 34 The primary tumour and the secondary deposits typically show decreased enhancement and may become completely cystic after chemotherapy. Sometimes, there may be a paradoxical early increase in the size of the masses and this should not be inferred as disease progression.…”
Section: Gastrointestinal Stromal Tumourmentioning
confidence: 99%
“…Chemotherapy (Imatinib) is the treatment of choice for patients with recurring or metastatic GIST. 34 The primary tumour and the secondary deposits typically show decreased enhancement and may become completely cystic after chemotherapy. Sometimes, there may be a paradoxical early increase in the size of the masses and this should not be inferred as disease progression.…”
Section: Gastrointestinal Stromal Tumourmentioning
confidence: 99%
“…They were mutations in the PDGFRA juxtamembrane domain (encoded by exon 12), the ATPbinding domain (encoded by exon 14) or the activation loop (encoded by exon 18) (43)(44)(45)53).…”
Section: The Possible Cellular Origin Of Primary Gistmentioning
confidence: 99%
“…KIT is a member of the type III transmembrane receptor tyrosine kinase family (39). 70-80% of GIST possess a KIT gene mutation, which were found at exon 11(50-77%), exon 9 (10-18%), exons 13 (1-4%) and exons 17 (1-4%) (40)(41)(42)(43)(44)(45)(46). All of the above are the first diagnostic biomarkers.…”
Section: The Diagnostic Biomarkers Of Primary Gistmentioning
confidence: 99%
“…According to major guidelines such as the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), the definitive final diagnosis of SETs should be based on immunohistochemistry (4)(5)(6)(7)(8). Immunohistochemical staining of various cellular proteins can be performed on tissue samples to provide diagnostic information.…”
Section: Introductionmentioning
confidence: 99%